"Heparin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.
| Descriptor ID |
D006493
|
| MeSH Number(s) |
D09.698.373.400
|
| Concept/Terms |
Heparin- Heparin
- Unfractionated Heparin
- Heparin, Unfractionated
- Heparinic Acid
|
Below are MeSH descriptors whose meaning is more general than "Heparin".
Below are MeSH descriptors whose meaning is more specific than "Heparin".
This graph shows the total number of publications written about "Heparin" by people in this website by year, and whether "Heparin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 1 | 2 |
| 1994 | 0 | 3 | 3 |
| 1995 | 0 | 7 | 7 |
| 1996 | 0 | 2 | 2 |
| 1997 | 5 | 3 | 8 |
| 1998 | 1 | 2 | 3 |
| 1999 | 2 | 0 | 2 |
| 2000 | 0 | 3 | 3 |
| 2001 | 2 | 4 | 6 |
| 2002 | 3 | 1 | 4 |
| 2003 | 2 | 3 | 5 |
| 2004 | 3 | 6 | 9 |
| 2005 | 5 | 5 | 10 |
| 2006 | 6 | 3 | 9 |
| 2007 | 0 | 3 | 3 |
| 2008 | 2 | 4 | 6 |
| 2009 | 3 | 5 | 8 |
| 2010 | 0 | 2 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 2 | 2 |
| 2013 | 3 | 0 | 3 |
| 2014 | 3 | 2 | 5 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 2 | 4 |
| 2017 | 4 | 3 | 7 |
| 2018 | 3 | 1 | 4 |
| 2019 | 2 | 1 | 3 |
| 2020 | 0 | 2 | 2 |
| 2021 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Heparin" by people in Profiles.
-
Unfractionated and Low-Molecular-Weight Heparin for Bridging Patients with Left Ventricular Assist Device: An Event-Based Analysis. ASAIO J. 2021 12 01; 67(12):1277-1283.
-
Sulfated alginate/polycaprolactone double-emulsion nanoparticles for enhanced delivery of heparin-binding growth factors in wound healing applications. Colloids Surf B Biointerfaces. 2021 Dec; 208:112105.
-
Effectiveness and Safety of Twice- Versus Thrice-Daily Subcutaneous Heparin for Venous Thromboembolism Prophylaxis at a Large Academic Medical Center. Ann Pharmacother. 2022 05; 56(5):541-547.
-
Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 2021 May; 8(5):e334-e343.
-
Reduced cellular binding affinity has profoundly different impacts on the spread of distinct poxviruses. PLoS One. 2020; 15(4):e0231977.
-
Combinatorial therapy of sirolimus and heparin by nanocarrier inhibits restenosis after balloon angioplasty ex vivo. Nanomedicine (Lond). 2020 05; 15(12):1205-1220.
-
Periprocedural Heparin During Endovascular Treatment of Tandem Lesions in Patients with Acute Ischemic Stroke: A Propensity Score Analysis from TITAN Registry. Cardiovasc Intervent Radiol. 2019 Aug; 42(8):1160-1167.
-
AGA Clinical Practice Update: Coagulation in Cirrhosis. Gastroenterology. 2019 07; 157(1):34-43.e1.
-
Limited impact of clinician education on reducing inappropriate PF4 testing for heparin-induced thrombocytopenia. J Thromb Thrombolysis. 2019 Feb; 47(2):287-291.
-
Plasma exchange to remove heparin-induced thrombocytopenia antibodies and the use of heparin during cardiopulmonary bypass in critically ill cardiac patients. J Heart Lung Transplant. 2018 08; 37(8):1038-1040.